Dr. Sulaiman Al Habib Medical Services Group Company
4013.SRSAUHealthcare● Active
$218.70
+$2.50(+1.16%)
Market Cap$76.5B
P/E Ratio—
52W High$281.2
52W Low$211.5
Dr. Sulaiman Al Habib Medical Services Group Company (4013.SR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
4013.SR · earnings · updated Jun 15, 2026
Latest Earnings
Q2 FY2026Report Date: May 3, 2026EPS Actual
$1.43
Est. $1.97 · -27.4%
Revenue
$3.43B
Est. $3.59B · -4.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 3, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
4013.SR reports quarterly as a SAU-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
79
days
Expected Date
Sep 2, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away79
Expected DateSep 2, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $1.65 | — | — | — | $3.69B | — |
| ▼ Q2 FY2026 | May 3, 2026 | $1.97 | $1.43 | -27.4% | $3.43B | $3.59B | -4.6% |
| ▲ Q1 FY2026 | Feb 15, 2026 | $1.76 | $1.86 | +5.7% | $3.69B | $3.63B | +1.7% |
| ▼ Q4 FY2025 | Oct 26, 2025 | $1.77 | $1.72 | -2.8% | $3.46B | $3.56B | -2.6% |
| ▲ Q3 FY2025 | Jul 27, 2025 | $1.63 | $1.69 | +3.7% | $3.38B | $3.28B | +3.2% |
| ▼ Q2 FY2025 | May 4, 2025 | $1.73 | $1.59 | -8.1% | $3.16B | $3.15B | +0.1% |
| ▲ Q1 FY2025 | Feb 17, 2025 | $1.62 | $1.75 | +8.0% | $3.13B | $3.15B | -0.6% |
| ▼ Q4 FY2024 | Nov 3, 2024 | $1.72 | $1.70 | -1.2% | $2.98B | $2.78B | +7.0% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$1.65
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 3, 2026Miss
EPS Actual
$1.43
EPS Est.
$1.97
EPS Surpr.
-27.4%
Revenue
$3.43B
Q1 FY2026
Feb 15, 2026Beat
EPS Actual
$1.86
EPS Est.
$1.76
EPS Surpr.
+5.7%
Revenue
$3.69B
Q4 FY2025
Oct 26, 2025Miss
EPS Actual
$1.72
EPS Est.
$1.77
EPS Surpr.
-2.8%
Revenue
$3.46B
Q3 FY2025
Jul 27, 2025Beat
EPS Actual
$1.69
EPS Est.
$1.63
EPS Surpr.
+3.7%
Revenue
$3.38B
Q2 FY2025
May 4, 2025Miss
EPS Actual
$1.59
EPS Est.
$1.73
EPS Surpr.
-8.1%
Revenue
$3.16B
Q1 FY2025
Feb 17, 2025Beat
EPS Actual
$1.75
EPS Est.
$1.62
EPS Surpr.
+8.0%
Revenue
$3.13B
Q4 FY2024
Nov 3, 2024Miss
EPS Actual
$1.70
EPS Est.
$1.72
EPS Surpr.
-1.2%
Revenue
$2.98B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $2.59 | $2.59 | $2.59 | 1 |
| Q3 FY2028 | $2.45 | $2.45 | $2.45 | 1 |
| Q2 FY2028 | $1.98 | $1.98 | $1.98 | 1 |
| Q1 FY2028 | $2.36 | $2.36 | $2.36 | 1 |
| Q4 FY2027 | $2.21 | $2.21 | $2.21 | 1 |
| Q3 FY2027 | $2.10 | $2.10 | $2.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $5.0B | $5.0B | $5.0B | 1 |
| Q3 FY2028 | $4.7B | $4.7B | $4.7B | 1 |
| Q2 FY2028 | $4.3B | $4.3B | $4.3B | 1 |
| Q1 FY2028 | $4.4B | $4.4B | $4.4B | 1 |
| Q4 FY2027 | $4.6B | $4.6B | $4.6B | 1 |
| Q3 FY2027 | $4.3B | $4.3B | $4.3B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 3, 2026 | -27.4% | $242.40 | $232.00 | -4.29% |
| ▲ Q1 FY2026 | Feb 15, 2026 | +5.7% | $258.80 | $259.80 | +0.39% |
| ▼ Q4 FY2025 | Oct 26, 2025 | -2.8% | $273.20 | $274.20 | +0.37% |
| ▲ Q3 FY2025 | Jul 27, 2025 | +3.7% | $251.40 | $261.40 | +3.98% |
| ▼ Q2 FY2025 | May 4, 2025 | -8.1% | $289.00 | $282.80 | -2.15% |
| ▲ Q1 FY2025 | Feb 17, 2025 | +8.0% | $295.00 | $294.00 | -0.34% |
| ▼ Q4 FY2024 | Nov 3, 2024 | -1.2% | $286.20 | $288.40 | +0.77% |
| ▲ Q3 FY2024 | Jul 28, 2024 | +14.5% | $281.40 | $282.60 | +0.43% |
Q2 FY2026-4.29%
Report Date
May 3, 2026
EPS Beat/Miss
-27.4%
Price Before
$242.40
Price After
$232.00
Q1 FY2026+0.39%
Report Date
Feb 15, 2026
EPS Beat/Miss
+5.7%
Price Before
$258.80
Price After
$259.80
Q4 FY2025+0.37%
Report Date
Oct 26, 2025
EPS Beat/Miss
-2.8%
Price Before
$273.20
Price After
$274.20
Q3 FY2025+3.98%
Report Date
Jul 27, 2025
EPS Beat/Miss
+3.7%
Price Before
$251.40
Price After
$261.40
Q2 FY2025-2.15%
Report Date
May 4, 2025
EPS Beat/Miss
-8.1%
Price Before
$289.00
Price After
$282.80
Q1 FY2025-0.34%
Report Date
Feb 17, 2025
EPS Beat/Miss
+8.0%
Price Before
$295.00
Price After
$294.00
Q4 FY2024+0.77%
Report Date
Nov 3, 2024
EPS Beat/Miss
-1.2%
Price Before
$286.20
Price After
$288.40
Q3 FY2024+0.43%
Report Date
Jul 28, 2024
EPS Beat/Miss
+14.5%
Price Before
$281.40
Price After
$282.60
Avg Beat Reaction+1.11%
Avg Miss Reaction-1.33%
Beat Rate4 / 8 quarters
Largest Move-4.29% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: 4013.SR ends December
Dr. Sulaiman Al Habib Medical Services Group Company (4013.SR) most recently reported earnings on May 3, 2026 for Q2 FY2026, posting EPS of $1.43 — missing the analyst consensus of $1.97 by -27.4%. The next 4013.SR earnings date is expected around September 2, 2026.
Each quarter, investors track 4013.SR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. 4013.SR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
4013.SR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
4013.SR earnings · 5 questionsDr. Sulaiman Al Habib Medical Services Group Company's next earnings report is expected around September 2, 2026. 4013.SR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; 4013.SR historically reports after market close (AMC).
4013.SR earnings datewhen is 4013.SR earnings4013.SR next earnings datewhen does 4013.SR report earnings4013.SR earnings calendar
▸ Source: FMP · Dr. Sulaiman Al Habib Medical Services Group Company SEC filings · US GAAP · Dr. Sulaiman Al Habib Medical Services Group Company SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026